Loading clinical trials...
Loading clinical trials...
Ketogenic Diet Adjunctive to High Dose Methotrexate Chemotherapy for Primary Central Nervous System Lymphoma
Ketogenic diet has shown auxiliary effect on treatment of malignant tumors require high glucose consumption. This study is designed to evaluate the safety and efficacy of ketogenic diet adjunctive to high dose methotrexate(HD-MTX) chemotherapy for primary central nervous system lymphoma (PCNSL).
In a pilot study of primary central nervous system(CNS) lymphoma patients, ketogenic diet was given in adjunction with standard HD-MTX chemotherapy as interventional group; standard HD-MTX is given with routine diet as control group. The primary endpoint is the safety of ketogenic diet in PCNSL patients receiving chemotherapy, secondary endpoints include rate of complete remission, remission time, rate of tumor relapse and overall survival.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Start Date
January 1, 2017
Primary Completion Date
December 1, 2018
Completion Date
December 1, 2019
Last Updated
December 6, 2016
50
ESTIMATED participants
ketogenic diet
DIETARY_SUPPLEMENT
Routine diet
DIETARY_SUPPLEMENT
Lead Sponsor
Beijing Tiantan Hospital
NCT02203526
NCT03328078
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions